On February 25, 2011, Jeff Elias, MD, and a University of Virginia (UVA) team treated Billy Williams, the first essential tremor patient to receive focused ultrasound in North America.
The partnership between UVA, the Foundation, and Insightec led to this event, which ignited a sea change in therapy.
Circulation published feasibility results from the first 10 patients in a clinical trial to soften calcified aortic heart valves.
Six participants responded to the treatment, possibly due to a longer duration of therapy.
Cardiawave is developing their investigational Valvosoft® device to mechanically soften the hardened valves, improve valve function, and reduce symptoms.
The Alzheimer’s Drug Discovery Foundation seeks funding proposals that show potential for advancing discovery into meaningful therapeutics that treat, prevent, or slow Alzheimer’s disease or other dementias.
The opportunity provides up to $600,000 over two years plus project support from industry veterans.
The deadline for the letter of intent is April 23, 2021.
The Foundation's Chief Scientific Officer Jessica Foley, PhD, joins others to discuss opportunities and challenges for women scientists and business leaders.
